Changes in the epidemiology and ecology of H5N1 highly pathogenic avian influenza are devastating wild bird and poultry populations, farms and communities, and wild mammals worldwide. Having originated in farmed poultry, H5N1 viruses are now spread glo...
The control and elimination of vector-borne diseases require knowledge about how vector control affects the presence of vectors in areas of human exposure (ie, abundance) and how alterations in abundance affect disease incidence.1 In The Lancet Infecti...
Arboviral infections have hit South America heavily in the past decade, with the epidemic of Zika virus in 2015–16, and recurrent outbreaks of chikungunya and dengue, the latter of which is affecting Brazil with a particularly high number of cases this...
Ebola virus disease poses a recurring risk to human health. We conducted a systematic review (PROSPERO CRD42023393345) of Ebola virus disease transmission models and parameters published from database inception to July 7, 2023, from PubMed and Web of S...
The increasing detection of Neisseria gonorrhoeae isolates with an extensively drug-resistant phenotype (ie, ceftriaxone minimum inhibitory concentration [MIC] ≥0·125 mg/L, plus high-level resistance to azithromycin [MIC ≥256 mg/L])1 is of grave concer...
Preparedness and communication are key to preventing and tackling existing and future epidemics, whether caused by known, lesser-known, or unknown pathogens. We need to strengthen and speed up cooperation among health authorities at regional, national,...
A dengue vaccine that is equally immunogenic and effective against all four viral serotypes would address one of the top-ten public health needs.1,2 In 2015, Dengvaxia (CYD-TDV; Sanofi Pasteur, Paris, France) was licensed, followed by the second vaccin...
A dengue vaccine that is equally immunogenic and effective against all four viral serotypes would address one of the top-ten public health needs.1,2 In 2015, Dengvaxia (CYD-TDV; Sanofi Pasteur, Paris, France) was licensed, followed by the second vaccin...
A single dose of Butantan-DV was generally well tolerated and efficacious against symptomatic VCD (caused by DENV-1 and DENV-2) for a mean of 3·7 years. These findings support the continued development of Butantan-DV to prevent dengue disease in childr...
A single dose of Butantan-DV was generally well tolerated and efficacious against symptomatic VCD (caused by DENV-1 and DENV-2) for a mean of 3·7 years. These findings support the continued development of Butantan-DV to prevent dengue disease in childr...
The global health landscape is currently dominated by the threat of avian influenza, a public health challenge of unprecedented magnitude. We are on the brink of a potential crisis, where pandemic risk is severely underestimated and efforts to prepare ...
The global health landscape is currently dominated by the threat of avian influenza, a public health challenge of unprecedented magnitude. We are on the brink of a potential crisis, where pandemic risk is severely underestimated and efforts to prepare ...
Treatment with either dose of fosravuconazole was not superior to itraconazole, and the two doses had a numerically lower efficacy. However, fosravuconazole presented no new safety signals, and its lower pill burden and reduced risk of drug–drug intera...
Treatment with either dose of fosravuconazole was not superior to itraconazole, and the two doses had a numerically lower efficacy. However, fosravuconazole presented no new safety signals, and its lower pill burden and reduced risk of drug–drug intera...
Eumycetoma is a chronic and destructive fungal infection that mainly affects the extremities via the development of granulomatous subcutaneous masses.1 Occurring in tropical and subtropical regions, it is most commonly caused by the fungus Madurella my...
Eumycetoma is a chronic and destructive fungal infection that mainly affects the extremities via the development of granulomatous subcutaneous masses.1 Occurring in tropical and subtropical regions, it is most commonly caused by the fungus Madurella my...